Klaudia Naegele1, Irmeli Lautenschlager2, Rainer Gosert3, Raisa Loginov4, Katia Bir5, Ilkka Helanterä6, Stefan Schaub7, Nina Khanna8, Hans H Hirsch9. 1. Division Infection Diagnostics, Department Biomedicine, University of Basel, Basel, Switzerland. Electronic address: Klaudia.Naegele@unibas.ch. 2. Helsinki University Hospital and University of Helsinki, Department of Virology, Finland. Electronic address: Irmeli.Lautenschlager@hus.fi. 3. Division Infection Diagnostics, Department Biomedicine, University of Basel, Basel, Switzerland. Electronic address: Rainer.Gosert@unibas.ch. 4. Helsinki University Hospital and University of Helsinki, Department of Virology, Finland. Electronic address: raisa.loginov@hus.fi. 5. Division Infection Diagnostics, Department Biomedicine, University of Basel, Basel, Switzerland. Electronic address: Katia.Bir@unibas.ch. 6. Helsinki University Hospital and University of Helsinki, Transplantation & Liver Surgery, Finland. Electronic address: Ilkka.Helantera@helsinki.fi. 7. Transplantation Immunology, Department Biomedicine, University of Basel, Basel, Switzerland. Electronic address: Stefan.schaub@usb.ch. 8. Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland. Electronic address: nina.khanna@usb.ch. 9. Division Infection Diagnostics, Department Biomedicine, University of Basel, Basel, Switzerland; Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland; Transplantation & Clinical Virology, Department Biomedicine, University of Basel, Basel, Switzerland. Electronic address: hans.hirsch@unibas.ch.
Abstract
BACKGROUND: Cytomegalovirus (CMV) management post-transplantation relies on quantification in blood, but inter-laboratory and inter-assay variability impairs commutability. An international multicenter study demonstrated that variability is mitigated by standardizing plasma volumes, automating DNA extraction and amplification, and calibration to the 1st-CMV-WHO-International-Standard as in the FDA-approved Roche-CAP/CTM-CMV. However, Roche-CAP/CTM-CMV showed under-quantification and false-negative results in a quality assurance program (UK-NEQAS-2014). OBJECTIVES: To evaluate factors contributing to quantification variability of CMV viral load and to develop optimized CMV-UL54-QNAT. STUDY DESIGN: The UL54 target of the UK-NEQAS-2014 variant was sequenced and compared to 329 available CMV GenBank sequences. Four Basel-CMV-UL54-QNAT assays of 361 bp, 254 bp, 151 bp, and 95 bp amplicons were developed that only differed in reverse primer positions. The assays were validated using plasmid dilutions, UK-NEQAS-2014 sample, as well as 107 frozen and 69 prospectively collected plasma samples from transplant patients submitted for CMV QNAT, with and without DNase-digestion prior to nucleic acid extraction. RESULTS: Eight of 43 mutations were identified as relevant in the UK-NEQAS-2014 target. All Basel-CMV-UL54 QNATs quantified the UK-NEQAS-2014 but revealed 10-fold increasing CMV loads as amplicon size decreased. The inverse correlation of amplicon size and viral loads was confirmed using 1st-WHO-International-Standard and patient samples. DNase pre-treatment reduced plasma CMV loads by >90% indicating the presence of unprotected CMV genomic DNA. CONCLUSIONS: Sequence variability, amplicon length, and non-encapsidated genomes obstruct standardization and commutability of CMV loads needed to develop thresholds for clinical research and management. Besides regular sequence surveys, matrix and extraction standardization, we propose developing reference calibrators using 100 bp amplicons.
BACKGROUND: Cytomegalovirus (CMV) management post-transplantation relies on quantification in blood, but inter-laboratory and inter-assay variability impairs commutability. An international multicenter study demonstrated that variability is mitigated by standardizing plasma volumes, automating DNA extraction and amplification, and calibration to the 1st-CMV-WHO-International-Standard as in the FDA-approved Roche-CAP/CTM-CMV. However, Roche-CAP/CTM-CMV showed under-quantification and false-negative results in a quality assurance program (UK-NEQAS-2014). OBJECTIVES: To evaluate factors contributing to quantification variability of CMV viral load and to develop optimized CMV-UL54-QNAT. STUDY DESIGN: The UL54 target of the UK-NEQAS-2014 variant was sequenced and compared to 329 available CMV GenBank sequences. Four Basel-CMV-UL54-QNAT assays of 361 bp, 254 bp, 151 bp, and 95 bp amplicons were developed that only differed in reverse primer positions. The assays were validated using plasmid dilutions, UK-NEQAS-2014 sample, as well as 107 frozen and 69 prospectively collected plasma samples from transplant patients submitted for CMV QNAT, with and without DNase-digestion prior to nucleic acid extraction. RESULTS: Eight of 43 mutations were identified as relevant in the UK-NEQAS-2014 target. All Basel-CMV-UL54 QNATs quantified the UK-NEQAS-2014 but revealed 10-fold increasing CMV loads as amplicon size decreased. The inverse correlation of amplicon size and viral loads was confirmed using 1st-WHO-International-Standard and patient samples. DNase pre-treatment reduced plasma CMV loads by >90% indicating the presence of unprotected CMV genomic DNA. CONCLUSIONS: Sequence variability, amplicon length, and non-encapsidated genomes obstruct standardization and commutability of CMV loads needed to develop thresholds for clinical research and management. Besides regular sequence surveys, matrix and extraction standardization, we propose developing reference calibrators using 100 bp amplicons.
Authors: Raymund R Razonable; Naoki Inoue; Swetha G Pinninti; Suresh B Boppana; Tiziana Lazzarotto; Liliana Gabrielli; Giuliana Simonazzi; Philip E Pellett; D Scott Schmid Journal: J Infect Dis Date: 2020-03-05 Impact factor: 5.226
Authors: R T Hayden; Y Su; J Boonyaratanakornkit; L Cook; Z Gu; K R Jerome; B A Pinsky; S S Sam; S K Tan; H Zhu; L Tang; A M Caliendo Journal: J Clin Microbiol Date: 2022-08-23 Impact factor: 11.677
Authors: Seema A Mehta Steinke; Mona Alfares; Alexandra Valsamakis; Shmuel Shoham; Ravit Arav-Boger; Laura Lees; Darin Ostrander; Michael S Forman; Audra Shedeck; Richard F Ambinder; Richard John Jones; Robin K Avery Journal: Transpl Infect Dis Date: 2020-12-02
Authors: Isabelle P Lodding; Mette Jørgensen; Marc Bennedbæk; Nikolai Kirkby; Klaudia Naegele; Finn Gustafsson; Michael Perch; Allan Rasmussen; Henrik Sengeløv; Søren S Sørensen; Hans H Hirsch; Jens D Lundgren Journal: Open Forum Infect Dis Date: 2021-09-04 Impact factor: 3.835
Authors: Cassia F B Caurio; Odelta S Allende; Roger Kist; Kênya L Santos; Izadora C S Vasconcellos; Franciéli P Rozales; Daiane F Dalla Lana; Bruno M Praetzel; Ana Paula Alegretti; Alessandro C Pasqualotto Journal: J Bras Nefrol Date: 2021 Oct-Dec
Authors: Cássia F B Caurio; Odelta S Allende; Roger Kist; Izadora C S Vasconcellos; Francieli P Rozales; Maikel Reck-Kortmann; Daiane F Dalla Lana; Ana Paula Alegretti; Giácomo B Neto; Alessandro C Pasqualotto Journal: Braz J Infect Dis Date: 2020-05-23 Impact factor: 3.257